Texas Children’s Hospital and Baylor College of Medicine announced that their "protein sub-unit COVID-19 Vaccine" has received Emergency Use Authorization (EUA) approval from the Drugs Controller General of India (DCGI) to launch in India with other underserved countries to follow as evidenced by the following tweet:
https://preview.redd.it/zwh8cla7fc881.png?width=737&format=png&auto=webp&s=1d3eef1c10c7490d2b360fdc7375443e5f8e649c
Why is this important to Amyris investors?
We look to Immunity Bio's 12.20.2021 press release for clues:
>Heterologous Mix-and-Match Program
>
>ImmunityBio has acquired the rights to multiple platforms and initiated a consortium including Baylor Medical College, Infectious Disease Research Institute (IDRI), Amyris, Inc. and EnGeneIC to develop, manufacture and scale second-generation vaccines that combine different advanced DNA, RNA, protein constructs, and adjuvants. The company has adopted a long-term approach to addressing COVID and future pandemics and believes these mix-and-match components are critical to providing accessible, broad, and durable protection against current and future variants such as Delta and Omicron variants.
>
>“Developing a novel vaccine candidate during a global pandemic has been challenging for a number of reasons, which have affected all drug developers,” said Soon-Shiong. “When we first announced our intent to develop a COVID-19 vaccine in April 2020, we indicated a vaccine that generates long-lasting, cell-mediated T cell immunity would require the use of genomics, molecular dynamics, and new vectors. We also hypothesized that a heterologous approach (mix-and-match) would strengthen immune response. Almost two years into the pandemic and dozens of virus mutations later, these predictions are proving more accurate than ever, which is why we are partnering with IDRI, Amyris, Inc., EnGeneIC, and the Baylor College of Medicine to develop next generation mRNA, recombinant protein vaccine candidates and first-in-class invariant NK-T Cell (iNK-T) COVID vaccines. We anticipate being able to move quickly to enroll participants in our COVID-19
my_qualifications -
MHT CET : 95.35 %ile
JEE Main : 86.33 %ile
After the jee mains results I had taken admission into CSE in Ramrao Adik Institute of Technology (RAIT) ,Nerul as my marks weren't very good and this was the only good college i was getting. But in MHT CET I have some chances of getting a good college. Right now I am getting admission in CE in Vidyalayankar Institute of Technology (VIT) through institute level seats and also AI and DS Fr. Agnel bandra through CAP round 1. But I live in thane and bandra is too far for daily travel and VIT is also kind of far so I'm confused as to take VIT or continue in RAIT. Please help.
Lanchester Submachinegun
https://preview.redd.it/jwqe0678ah971.jpg?width=377&format=pjpg&auto=webp&s=9779a8e8e747282a9e851d4b4babf1f94be281ad
MTTK: 0.2 seconds
Multipliers: 1.40x head, 1.10x torso
DMG Ranges: 40-110 studs
Accuracy: Bouncy and backwards recoil at 600 RPM that leans left, 0 choke, 1,350 studs of muzzle velocity
Penetration: 0.5 studs
Suppression: 0.2
Ammo Capacity: 50/150
Damage: 34-23
Reload: 2.6 or 2 seconds wet, 3 or 2.4 seconds dry
Walkspeed: 13.5 or 14 studs/second
Chambering: 9x19mm Parabellum
Attachments of note: 32 round mag
please give feedback in comments.
